Chronic Pelvic Pain Syndrome: Reduction of Medication Use After Pelvic Floor Physical Therapy with an Internal Myofascial Trigger Point Wand
- 917 Downloads
This study documents the voluntary reduction in medication use in patients with refractory chronic pelvic pain syndrome utilizing a protocol of pelvic floor myofascial trigger point release with an FDA approved internal trigger point wand and paradoxical relaxation therapy. Self-referred patients were enrolled in a 6-day training clinic from October, 2008 to May, 2011 and followed the protocol for 6 months. Medication usage and symptom scores on a 1–10 scale (10 = most severe) were collected at baseline, and 1 and 6 months. All changes in medication use were at the patient’s discretion. Changes in medication use were assessed by McNemar’s test in both complete case and modified intention to treat (mITT) analyses. 374 out of 396 patients met inclusion criteria; 79.7 % were male, median age of 43 years and median symptom duration of 5 years. In the complete case analysis, the percent of patients using medications at baseline was 63.6 %. After 6 months of treatment the percentage was 40.1 %, a 36.9 % reduction (p < 0.001). In the mITT analysis, there was a 22.7 % overall reduction from baseline (p < 0.001). Medication cessation at 6 months was significantly associated with a reduction in total symptoms (p = 0.03).
KeywordsMyofascial trigger point release Chronic pelvic pain syndrome Paradoxical relaxation Physical therapy
Chronic prostatitis/chronic pelvic pain syndrome
Urologic chronic pelvic pain syndrome
National Institutes of Health Chronic Prostatitis Symptoms
Conflict of interest
R. U. Anderson is a consultant to New Pelvic Pain Technologies, Inc. and holds intellectual property royalty relationship. D. Wise is founder and owner of New Pelvic Pain Technologies, Inc. T. Sawyer is a consultant and holds stock relationship with New Pelvic Pain Technologies, Inc. Brian H. Nathanson, through his company OptiStatim, LLC, has received consulting fees from New Pelvic Pain Technologies, Inc.
- Anderson, R. U., Wise, D., Sawyer, T., Glowe, P., & Orenberg, E. K. (2011a). 6-Day intensive treatment protocol for refractory chronic prostatitis/chronic pelvic pain syndrome using myofascial release and paradoxical relaxation training. The Journal of Urology, 185(4), 1294–1299.CrossRefPubMedGoogle Scholar
- Dellit, T. H., Owens, R. C., McGowan, J. E., Gerding, D. N., Weinstein, R. A., Burke, J. P., & Hooton, T. M. (2007). Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clinical Infectious Diseases, 44(2), 159–177.CrossRefPubMedGoogle Scholar
- FitzGerald, M. P., Anderson, R. U., Potts, J., Payne, C. K., Peters, K. M., Clemens, J. Q., & Nyberg, L. M. (2009). Randomized multicenter feasibility trial of myofascial physical therapy for the treatment of urological chronic pelvic pain syndromes. The Journal of Urology, 182(2), 570–580.CrossRefPubMedCentralPubMedGoogle Scholar
- FitzGerald, M. P., Payne, C. K., Lukacz, E. S., Yang, C. C., Peters, K. M., Chai, T. C., & Nyberg, L. M. (2012). Randomized multicenter clinical trial of myofascial physical therapy in women with interstitial cystitis/painful bladder syndrome and pelvic floor tenderness. The Journal of Urology, 187(6), 2113–2118.CrossRefPubMedCentralPubMedGoogle Scholar
- Shoskes, D. A., Nickel, J. C., Rackley, R. R., & Pontari, M. A. (2008b). Clinical phenotyping in chronic prostatitis/chronic pelvic pain syndrome and interstitial cystitis: A management strategy for urologic chronic pelvic pain syndromes. Prostate cancer and prostatic diseases, 12(2), 177–183.CrossRefPubMedGoogle Scholar
- Wise, D., & Anderson, R. U. (2012). A headache in the pelvis: A new understanding and treatment for prostatitis and chronic pelvic pain syndromes (6th ed.). Occidental, CA: National Center for Pelvic Pain.Google Scholar